Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.

Trial Details

NCT ID
NCT05280314
Phase
PHASE2
Sponsor
IO Biotech
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • IO102-IO103
  • Pembrolizumab KEYTRUDA®
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Richmond, Virginia, United States|37.55376,-77.46026
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Melbourne, Victoria, Australia|-37.814,144.96332

Key Eligibility Criteria

  • Histologically or cytologically confirmed diagnosis of cutaneous stage III melanoma according to the American Joint Committee on Cancer (AJCC) 8th …
  • Patients with resectable tumors are eligible for this trial either at presentation for primary melanoma with concurrent regional nodal metastasis o…
  • Primary cutaneous melanoma with clinically apparent regional lymph node metastases
  • Clinically detected recurrent melanoma at the proximal regional lymph node(s) basin

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →